EnBiotix Reports Publication Highlighting Anti-persister Agent Targeting Antibiotic-Tolerant Infections in Antimicrobial Agents and Chemotherapy
PRESS RELEASE | CAMBRIDGE, Mass. and LEIPZIG, Germany (October 2nd, 2017) – EnBiotix, Inc., a product-focused bioengineering company leveraging systems and synthetic biology platforms to combat the global rise of drug-resistant and drug-tolerant bacterial infections, announced today a publication in Antimicrobial Agents & Chemotherapy , a journal of the American Society for Microbiology, detailing data on EBX-001, the Company’s lead product for the treatment of Pseudomonas aeruginosa infections. The paper titled, “An Anti-Persister Strategy for the Treatment of Chronic Pseudomonas aeruginosa Infections,” was co-authored by a team of scientists from Massachusetts General Hospital, Harvard Medical School, the Geisel School of Medicine at Dartmouth and EnBiotix.
Full Press Release at BusinessWire | October 2nd, 2017